Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Terazosin Hydrochloride

FDA-approved product (tablet, oral), marketed as Hytrin, Terazosin Hydrochloride, Tezruly.

Registered studies
41
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Terazosin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Benign prostatic hyperplasia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Alpha-adrenoreceptor antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae40.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

41registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Terazosin Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Terazosin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence

    NCT01390870 · start 2009-05

    Registered record
    Registry ID
    NCT01390870
    Conditions
    Prostatic Hyperplasia
    Interventions
    5ARI or AB or Combination Therapy (5ARI + AB)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-05
    Completion
    2010-09
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    Intervention5ARI or AB or Combination Therapy (5ARI + AB)
    PhaseNot recorded
    Registry statusCompleted

  • Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment

    NCT01386983 · start 2009-03

    Registered record
    Registry ID
    NCT01386983
    Conditions
    Prostatic Hyperplasia
    Interventions
    5ARI; 5ARI + AB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-03
    Completion
    2010-06
    Enrolment
    332

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    Intervention5ARI; 5ARI + AB
    PhaseNot recorded
    Registry statusCompleted

  • The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia

    NCT00687388 · start 2008-05

    Registered record
    Registry ID
    NCT00687388
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    selective alpha 1-blockers; celecoxib; alpha-blocker and NSAID
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2008-05
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    Interventionselective alpha 1-blockers; celecoxib; alpha-blocker and NSAID
    PhasePhase 4
    Registry statusWithdrawn

  • Alpha-blocker Plus Diuretic Combination Therapy as Second-line Treatment for Nocturia in Men

    NCT00700583 · start 2008-05

    Registered record
    Registry ID
    NCT00700583
    Conditions
    Nocturia
    Interventions
    combination therapy of terazosin and hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-05
    Completion
    2008-06
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNocturia
    Interventioncombination therapy of terazosin and hydrochlorothiazide
    PhaseNot applicable
    Registry statusCompleted

  • Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin

    NCT00449683 · start 2007-03

    Registered record
    Registry ID
    NCT00449683
    Conditions
    Hyperhidrosis
    Interventions
    terazosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-03
    Completion
    2013-08
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperhidrosis
    Interventionterazosin
    PhasePhase 4
    Registry statusCompleted

  • Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension

    NCT00693199 · start 2006-07

    Registered record
    Registry ID
    NCT00693199
    Conditions
    Lower Urinary Tract Symptoms; Hypertension
    Interventions
    amlodipine; terazosin; amlodipine plus terazosin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-07
    Completion
    2006-10
    Enrolment
    360

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLower Urinary Tract Symptoms; Hypertension
    Interventionamlodipine; terazosin; amlodipine plus terazosin
    PhaseNot applicable
    Registry statusCompleted

  • Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up

    NCT00563485 · start 2005-10

    Registered record
    Registry ID
    NCT00563485
    Conditions
    Prostatic Hyperplasia; Urinary Retention
    Interventions
    Doxazosin GITS (Cardura XL); Terazosin (Hytrin)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2005-10
    Completion
    2006-11
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia; Urinary Retention
    InterventionDoxazosin GITS (Cardura XL); Terazosin (Hytrin)
    PhaseNot applicable
    Registry statusTerminated

  • Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating

    NCT00237510 · start 2005-05

    Registered record
    Registry ID
    NCT00237510
    Conditions
    Antidepressant Induced Excessive Sweating
    Interventions
    terazosin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-05
    Completion
    2007-05
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntidepressant Induced Excessive Sweating
    Interventionterazosin
    PhaseNot applicable
    Registry statusCompleted

  • Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension

    NCT00684489 · start 2003-09

    Registered record
    Registry ID
    NCT00684489
    Conditions
    Hypertension
    Interventions
    clinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med.
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-09
    Completion
    2005-09
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionclinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med.
    PhaseNot applicable
    Registry statusCompleted

  • Action to Control Cardiovascular Risk in Diabetes (ACCORD)

    NCT00000620 · start 1999-09

    Registered record
    Registry ID
    NCT00000620
    Conditions
    Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia; Hypertension; Diabetes Mellitus, Type 2; Diabetes Mellitus; Coronary Disease
    Interventions
    Anti-hyperglycemic Agents; Anti-hypertensive Agents; Blinded fenofibrate or placebo plus simvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1999-09
    Completion
    2012-12
    Enrolment
    10,251

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtherosclerosis; Cardiovascular Diseases; Hypercholesterolemia; Hypertension +3 more
    InterventionAnti-hyperglycemic Agents; Anti-hypertensive Agents; Blinded fenofibrate or placebo plus simvastatin
    PhasePhase 3
    Registry statusCompleted

  • FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia

    NCT02244255 · start 1998-08

    Registered record
    Registry ID
    NCT02244255
    Conditions
    Prostatic Hyperplasia
    Interventions
    FLOMAX® capsules; Ascending doses of HYTRIN® capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    1998-08
    Completion
    Not recorded
    Enrolment
    1,993

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    InterventionFLOMAX® capsules; Ascending doses of HYTRIN® capsules
    PhasePhase 4
    Registry statusCompleted